- Home
- IDYA vs VNET Comparison
IDYA vs VNET Comparison
Compare IDYA & VNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- VNET
- Stock Information
- Founded
- IDYA 2015
- VNET 1999
- Country
- IDYA United States
- VNET China
- Employees
- IDYA N/A
- VNET N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- VNET Computer Software: Programming Data Processing
- Sector
- IDYA Health Care
- VNET Technology
- Exchange
- IDYA Nasdaq
- VNET Nasdaq
- Market Cap
- IDYA 2.3B
- VNET 2.6B
- IPO Year
- IDYA 2019
- VNET 2011
- Fundamental
- Price
- IDYA $32.18
- VNET $11.04
- Analyst Decision
- IDYA Buy
- VNET Strong Buy
- Analyst Count
- IDYA 17
- VNET 3
- Target Price
- IDYA $48.20
- VNET $13.20
- AVG Volume (30 Days)
- IDYA 1.3M
- VNET 5.3M
- Earning Date
- IDYA 11-04-2025
- VNET 11-19-2025
- Dividend Yield
- IDYA N/A
- VNET N/A
- EPS Growth
- IDYA N/A
- VNET N/A
- EPS
- IDYA N/A
- VNET N/A
- Revenue
- IDYA $7,000,000.00
- VNET $1,262,962,115.00
- Revenue This Year
- IDYA $90.17
- VNET $18.94
- Revenue Next Year
- IDYA $219.42
- VNET $19.44
- P/E Ratio
- IDYA N/A
- VNET $506.83
- Revenue Growth
- IDYA N/A
- VNET 17.85
- 52 Week Low
- IDYA $13.45
- VNET $3.25
- 52 Week High
- IDYA $33.64
- VNET $16.13
- Technical
- Relative Strength Index (RSI)
- IDYA 67.18
- VNET 63.04
- Support Level
- IDYA $28.17
- VNET $9.91
- Resistance Level
- IDYA $33.64
- VNET $9.50
- Average True Range (ATR)
- IDYA 1.68
- VNET 0.58
- MACD
- IDYA 0.40
- VNET 0.11
- Stochastic Oscillator
- IDYA 80.76
- VNET 80.88
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved to the data center business with its first self-developed data center opening in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of June 2025, it had 51,960 retail cabinets with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 674 MW of wholesale capacity in service with a further 326 MW under construction and a further 792 MW held for future development.